Analyst Expectations For Beauty Health's Future
Portfolio Pulse from Benzinga Insights
Analyst ratings for Beauty Health (NASDAQ:SKIN) have been updated, with 5 analysts providing evaluations in the last three months. The average 12-month price target for SKIN has been raised to $3.6, a 38.46% increase from the previous target of $2.60. Analysts' sentiments have shifted slightly towards a more neutral stance, with recent ratings indicating 4 indifferent and 1 somewhat bearish outlooks. Beauty Health's financial performance shows a decline in revenue growth and challenges in ROE, but a strong net margin and ROA. The company's debt-to-equity ratio is higher than the industry average, indicating a reliance on borrowed funds.
March 14, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Beauty Health's average 12-month price target has been raised to $3.6, reflecting a 38.46% increase. Analysts show a neutral to slightly bearish stance. Financial challenges include a revenue decline and high debt-to-equity ratio, but the company maintains a strong net margin and ROA.
The raised price target suggests a positive outlook on the company's valuation, despite the neutral to somewhat bearish sentiment from analysts. The financial performance indicators such as the decline in revenue and high debt-to-equity ratio could concern investors, but the strong net margin and ROA may offset these concerns in the short term. The overall neutral score reflects the mixed signals from financial performance and analyst sentiments.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100